Aquestive Therapeutics, Inc. $AQST Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets lifted its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 6,233.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,171,675 shares of the company’s stock after purchasing an additional 1,153,175 shares during the period. BNP Paribas Financial Markets’ holdings in Aquestive Therapeutics were worth $7,569,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Victory Capital Management Inc. boosted its holdings in shares of Aquestive Therapeutics by 17.0% during the 3rd quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock worth $72,000 after purchasing an additional 1,862 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Aquestive Therapeutics by 6.0% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock worth $156,000 after purchasing an additional 2,649 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Aquestive Therapeutics by 16.6% in the second quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company’s stock valued at $106,000 after acquiring an additional 4,557 shares during the last quarter. NewEdge Advisors LLC acquired a new position in Aquestive Therapeutics in the third quarter valued at approximately $28,000. Finally, ProShare Advisors LLC lifted its holdings in Aquestive Therapeutics by 28.7% in the fourth quarter. ProShare Advisors LLC now owns 24,482 shares of the company’s stock valued at $158,000 after acquiring an additional 5,461 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Trading Up 2.0%

Aquestive Therapeutics stock opened at $3.99 on Wednesday. Aquestive Therapeutics, Inc. has a twelve month low of $2.93 and a twelve month high of $7.55. The stock’s fifty day simple moving average is $4.14 and its 200-day simple moving average is $4.52. The firm has a market capitalization of $500.55 million, a P/E ratio of -6.54 and a beta of 1.46.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.07. The company had revenue of $14.45 million for the quarter, compared to analysts’ expectations of $10.90 million. Sell-side analysts predict that Aquestive Therapeutics, Inc. will post -0.41 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Daniel Barber sold 8,257 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $4.29, for a total value of $35,422.53. Following the transaction, the chief executive officer owned 660,574 shares of the company’s stock, valued at $2,833,862.46. This represents a 1.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on AQST shares. Oppenheimer started coverage on Aquestive Therapeutics in a report on Friday, April 24th. They issued an “outperform” rating and a $8.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Monday, April 20th. Finally, Wall Street Zen upgraded Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $8.80.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.